Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03832738 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
A Phase 2 study of Psoriasis and Plaque Psoriasis, sponsored by Akros Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 152
- Enrollment target
- 20
- Study locations
NCT03832738: Completed Phase 2 study of Psoriasis and Plaque Psoriasis, sponsored by Akros Pharma.
NCT03832738 is a Phase 2 study of Psoriasis and Plaque Psoriasis that has completed, run by Akros Pharma. The registered enrollment target is 152 participants, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (69% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03832738, a Phase 2 study of Psoriasis and Plaque Psoriasis, has completed, sponsored by Akros Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 152 participants
- Enrollment target
- 20
- Study locations
Study Summary
Study to evaluate the efficacy and safety of JTE-451 administered for 16 weeks in subjects with moderate to severe plaque psoriasis.
Primary Outcome
The psoriasis area and severity index (PASI) combines the assessment of the severity of lesions (scaling, redness and plaque thickness) and the area affected into a single score in the range of 0.0 (no disease) to 72.0 (maximal disease). The body is divided into four sections: (1) Head and neck; (2) Upper limbs; (3) Trunk (including axillae and groin); and (4) Lower limbs (including buttocks). The PASI score can vary in increments of 0.1 and range from 0.0 to 72.0, with higher scores representi
Conditions Studied
Interventions
- DRUG Placebo Tablets
- DRUG JTE-451 Tablets
Study Locations (20)
Other
- Szpital Uniwersytecki nr 1 im. Dr. A. Jurasza w Bydgoszczy, Klinika Dermatologii, Chorob Prenoszonych Droga Plciowa - Bydgoszcz
- Copernicus Podmiot Leczniczy Sp. z o.o., Oddzial Dermatologii - Gdansk
- Prywatny Gabinet Dermatologiczny Elzbieta Klujszo - Kielce
- Centrum Nowoczesnych Terapii "Dobry Lekarz" Spolka z orgraniczona odpowiedzialnoscia - Krakow
- Centrum Terapii Wspolczesnej J.M. Jasnorzewska Spolka Komandytowo-Akeyjna - Lodz
- ETG Lodz - Lodz
- Dermoklinika - Centrum Medyczne s.c., M. Kierstan, J. Narbutt, A. Lesiak - Lodz
- ETG Lublin - Lublin
Ontario
- SimcoDerm Medical and Surgical Dermatology Center - Barrie
- SKiN Health - Cobourg
- Research Toronto - Toronto
- K. Papp Clinical Research - Waterloo
California
- Clinical Science Institute - Santa Monica
- Advanced Dermatology and Skin Cancer Specialists - Temecula
Indiana
- Dawes Fretzin Clinical Research Group, LLC - Indianapolis
Oklahoma
- Central Sooner Research - Norman
Rhode Island
- Rhode Island Hospital - Providence
South Dakota
- Health Concepts - Rapid City
Manitoba
- Wiseman Dermatology Research Inc. - Winnipeg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 152 participants |
| Start Date | 2019-01-17 |
| Est. Completion | 2020-03-13 |
| Phase | Phase 2 |
What the finished NCT03832738 record still lists
NCT03832738 is an interventional study that assigns participants to a tested intervention. The registered 152 participants enrollment target is mid-sized for trials with a published cap, below the 488-participant average among 125 other Psoriasis trials with a reported enrollment target (69% lower).
The record links to 3 conditions, with Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo Tablets is the first listed.
NCT03832738 names 20 study sites across 9 states, led by Other, Ontario, California.
Frequently Asked Questions
What is clinical trial NCT03832738 about?
NCT03832738 is a clinical study titled "Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis". Study to evaluate the efficacy and safety of JTE-451 administered for 16 weeks in subjects with moderate to severe plaque psoriasis.
What is the current status of trial NCT03832738?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 152 participants. The study started on 2019-01-17. Estimated completion is 2020-03-13.
What conditions does trial NCT03832738 study?
This clinical trial studies the following conditions: Psoriasis, Plaque Psoriasis, Skin Diseases.
What interventions are being tested in trial NCT03832738?
The interventions under investigation include: Placebo Tablets (DRUG), JTE-451 Tablets (DRUG).
Who is sponsoring clinical trial NCT03832738?
This trial is sponsored by Akros Pharma, which has 18 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03832738 being conducted?
This trial has 20 study locations across California, Indiana, Oklahoma, Rhode Island, South Dakota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03832738's enrollment target sits among peer trials
152 46th of 125 higher than 79 of 125 other Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study in Participants With Moderate to Severe Psoriasis
COMPLETED · Phase 2
-
A Study to Assess the Efficacy and Safety of PPC-06 (Tepilamide Fumarate)
COMPLETED · Phase 2
-
Etanercept With Tacrolimus for Psoriasis
COMPLETED · Phase 2
-
A Study of Safety, Tolerability and Pharmacokinetics of Apremilast (CC-10004) in Pediatric Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.
COMPLETED · Phase 2
-
Randomized Study of PH-10 for Psoriasis
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03328078 · 152 participants · Phase 1
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- NCT04458532 · 152 participants · NA
Exercise Therapy to Improve Cardiovascular Health in Post-Menopausal Women After Treatment for Early Stage Breast Cancer
- NCT04858334 · 152 participants · Phase 2
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
- NCT04993859 · 152 participants
Impact of Chemotherapy on Urinary Biomarkers and Non-Invasive Urodynamics in Children
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI